KANSAS CITY, Mo. and CAMBRIDGE, Mass., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Cerner Corp. (Nasdaq:CERN) and Claritas Genomics announce that the companies will work together to advance personalized medicine by building tools and connectivity that will better integrate next generation sequence (NGS)-based diagnostic testing into health care practice. The parties will collaborate to develop a rapid, scalable laboratory solution for molecular diagnostics that is tailored to NGS workflows, which are more complex and generate much more data than traditional molecular diagnostic tests.
Claritas will implement Cerner's Millennium Helix ® solution as part of the initial phase of the project, and will join Cerner's Reference Lab Network to allow seamless ordering and results return for other Reference Lab Network partners.
As part of the relationship, Cerner Capital, a wholly-owned subsidiary of Cerner, has invested in the company, becoming a minority shareholder and bringing to a close the company's Series A round. Clay Patterson, managing director of Cerner Capital, has joined Claritas's board of directors.Cambridge-based Claritas Genomics is a clinical diagnostics laboratory that provides genetic testing with a focus on pediatric medicine, combining advanced genetic analysis technology with clinical interpretive services that tap into the expertise of specialists at the best pediatric hospitals. The company was formed as a spin out of Boston Children's Hospital, with an investment from Life Technologies in February, and was recently joined by Cincinnati Children's Hospital, and now Cerner, as key investors and network partners. The relationship with Cerner will enable Claritas to tap into an existing, scalable computing infrastructure that integrates ordering of genomic sequencing tests, laboratory processing, results interpretation, return of results to the clinician and incorporation of the result in the patient's electronic medical record (EMR). "Cerner has long focused on the power of genomics and its impact to clinical processes, and this relationship will help advance the field and define a meaningful narrative in personalized medicine between the realms of research, diagnostics and clinical practice," said Dick Flanigan, senior vice president with Cerner. Claritas' focus on pediatrics is noteworthy, as that's when integrating genomics into clinical practice could be particularly impactful."
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts